How BCAL Diagnostics Is Expanding Early Cancer Detection Nationwide
BCAL Diagnostics is expanding access to its Avantect pancreatic and ovarian cancer blood tests across Australia through partnerships with major pathology providers. This move marks a significant step in making early cancer detection more widely available.
- Avantect tests now available in NSW, Queensland, and Victoria via Sonic Healthcare centres
- New agreement with Healius Pathology Network enables national access
- Tests use advanced genomic, epigenomic, and machine learning technologies
- Expansion builds on existing collaboration with Sonic Healthcare and BREASTEST plus
- Focus on early detection for patients at elevated risk of pancreatic and ovarian cancers
National Expansion of Avantect Tests
BCAL Diagnostics Limited (ASX:BDX) has announced a significant acceleration in the commercial rollout of its Avantect pancreatic and ovarian cancer blood tests. Following an initial launch at the Sydney Breast Clinic earlier this year, the tests are now accessible through selected Sonic Healthcare pathology collection centres in New South Wales, Queensland, and Victoria. A new agreement with Healius Pathology Network further extends availability to a national scale, making these advanced diagnostics more widely accessible to clinicians and patients across Australia.
Innovative Technology at the Forefront
The Avantect tests are designed to detect pancreatic and ovarian cancers at an early stage in patients identified as being at elevated risk. They leverage cutting-edge cell-free DNA analysis, combining genomic and epigenomic data with sophisticated machine learning algorithms. This integration provides doctors with enhanced diagnostic insights, potentially improving clinical outcomes by enabling earlier intervention when treatment options are more effective.
Strategic Collaborations Driving Growth
This rollout builds on BCAL’s existing partnership with Sonic Healthcare, which also supports the distribution of BCAL’s BREASTEST plus blood test for breast cancer evaluation. The collaboration with two of Australia’s leading pathology providers; Sonic Healthcare and Healius Pathology Network; positions BCAL to expand its footprint in the early cancer detection market. CEO Shane Ryan emphasised the importance of these partnerships in accelerating patient access to innovative diagnostics through established national collection networks.
Implications for Early Cancer Detection
Early detection remains a critical factor in improving survival rates for cancers that are often diagnosed late, such as pancreatic and ovarian cancers. By making these tests more widely available, BCAL is addressing a significant unmet need in oncology diagnostics. The company’s approach aligns with a broader healthcare trend towards non-invasive, blood-based tests that complement traditional screening methods.
Looking Ahead
While the announcement does not disclose specific sales targets or financial guidance, the national rollout represents a pivotal moment for BCAL Diagnostics. The company’s ability to drive clinician adoption and patient uptake will be key to translating this expanded access into commercial success. Investors and industry watchers will be keen to monitor how these tests perform in the competitive early detection landscape and whether further partnerships or regulatory milestones follow.
Bottom Line?
BCAL’s national rollout of Avantect tests could reshape early cancer detection, next steps will reveal its market impact.
Questions in the middle?
- How quickly will clinicians adopt Avantect tests across the expanded network?
- What commercial impact will the national rollout have on BCAL’s revenue?
- Are there plans to extend Avantect testing to other cancer types or regions?
